CTOs on the Move

Zucara Therapeutics

www.zucara.ca

 
Zucara Therapeutics, a CDRD and MaRS Innovation portfolio company, is developing the first drug therapy to prevent hypoglycemia in people with diabetes. Our first-in-class therapeutic is focused on improving glucagon counterregulation by inhibiting somatostatin which is dysregulated in Type 1 diabetes.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.zucara.ca
  • 4th Floor 2405 Wesbrook Mall
    Vancouver, BC CAN V6T 1Z3
  • Phone: N/A

Executives

Name Title Contact Details

Funding

Zucara Therapeutics raised $21M on 03/31/2020

Similar Companies

Apogee Therapeutics

Apogee Therapeutics is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and other inflammatory and immunology indications with high unmet need. Apogee`s antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. The company`s two most advanced programs are APG777 and APG808, which are being initially developed for the treatment of AD and COPD, respectively. Based on a broad pipeline and depth of expertise, the company believes it can deliver value and meaningful benefit to patients underserved by today`s standard of care.

Optimer Pharmaceuticals

Optimer Pharmaceuticals, Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Krystal Biotech

At Krystal Biotech, Inc., our mission is to make a meaningful difference in the lives of underserved patient populations suffering from debilitating skin diseases. We work to accomplish this goal through scientific innovation and operational excellence, believing that `nature operates in the shortest way possible`.

Nutrawise Corp

Nutrawise Corp is a Tustin, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Novavax

Novavax, Inc. (Nasdaq: NVAX), a clinical-stage biopharmaceutical company, employs its cutting-edge technology to create next-generation vaccines to prevent serious infectious diseases, such as pandemic and seasonal influenza and respiratory syncytial virus (RSV). The company’s proprietary virus-like-particle (VLP) technology and single-use bioprocessing system enable rapid vaccine development and production where and when they are needed, worldwide. The company has formed a joint venture with Cadila Pharmaceuticals, named CPL Biologicals, to develop and manufacture vaccines, biological therapeutics and diagnostics in India. Additional information about Novavax is available on the company’s website